KLAC · Investment summary · as of 3 August 2026
Priced slightly ahead of what the business has demonstrated
Business type: Cyclical · cyclical or commodity-sensitive
The operating path required by today's price is not achievable on the evidence.
At $182.74, KLAC requires a 30% five-year revenue growth rate to justify its enterprise value — more than the business has ever demonstrated, at 16%.
The conditions that would settle the disagreement are dated to September 2026.
The value rests on an exit multiple of 18.2x, a terminal operating margin of 39% and a 11.3% cost of capital. Move any one of them materially and the conclusion moves with it, which is why the required-versus-demonstrated test above carries more weight here than the point value.
The strongest argument against this view: Named cause: US export-control escalation extending licence requirements to KLA process-control tools for China domestic logic/mature-node and memory fabs.
| Question | Evidence-based conclusion |
|---|---|
| What drives the business? | Cyclical: revenue and margin driven by the exogenous WFE/fab-utilisation/memory cycle. FY2024 revenue -6.5%, FY2025 +23.9%, FY2026 +11.7%; 10-year GAAP operating margin span 25.9%-41.7%. |
| What do we forecast? | Revenue growth of 16% demonstrated; a terminal operating margin of 39%; an exit multiple of 18.2x. |
| What does Street forecast? | Not determined — no consensus estimates are joined to this record |
| Where do we differ? | On revenue growth, the difference between what the price requires and what the business has demonstrated is -13.4 percentage points. |
| What is it worth? | Twelve-month target $190.82, +4% from the struck price. Scenario-weighted expected return net of costs +4.4%. |
| Why now? | The first dated test of the thesis falls on 7 August 2026. |
| Date or window | Event | Thesis confirmed if | Thesis weakened or refuted if |
|---|---|---|---|
| 30 September 2026 | Total revenues | Q1 FY2027 revenue at or above $3.8bn | Q1 FY2027 revenue below $3.8bn |
| any two consecutive FY2027 quarters | Gross margin | GAAP gross margin at or above 59.0% for two consecutive quarters | GAAP gross margin below 59.0% for two consecutive quarters |
| 7 August 2026 | RPO | FY2026 10-K remaining performance obligation at or above $7.0bn | FY2026 10-K remaining performance obligation below $7.0bn |
| any | BIS/Commerce rulemaking (event) | Neither leg of the condition opposite is met at this date | New US rule extending export licence requirements to process-control tools for China domestic fabs |
Named cause: US export-control escalation extending licence requirements to KLA process-control tools for China domestic logic/mature-node and memory fabs. China was 43%/33% of revenue in FY2024/FY2025; assume half of China systems demand (~15% of total revenue) is permanently foreclosed, arriving together with a normal cyclical pause on a backlog cushion already 40% thinner (RPO $11.40bn -> $7.86bn FY2023-FY2025). Earnings power: revenue ~$10.2bn (-25%), through-cycle 10y median margin 37.4% -> EBIT ~$3.8bn, NOPAT ~$3.28bn vs $4.88bn today: a permanent ~33% earnings-power impairment. STATED LOSS: -35% of position value (earnings-power loss; multiple compression on top is a valuation event scored elsewhere, not double-counted here). Not a going-concern case ($985m net debt vs $3.8bn FCF).
Estimated probability 12%, against the 29% level at which the position would be resized. It sits within that level.
Falsifiable and fundamental — not one of them is a price condition.
At current spot forward E[R] is +4.4%, above the 0% hurdle, so this rung does not fire; the name is kept out by rank (a -13.4pp valuation margin does not compete for a slot), not by the sell rung. On approach to the $190.82 target the case is reviewed rather than added to; a target reached is a reason to re-examine the position, not to hold it by default. The position is trimmed once forward expected return falls below 0% net of costs, because the capital has a better use elsewhere in the book.
| Criteria | Status | Investment meaning |
|---|---|---|
| Quality | Met | Is the business worth owning under its declared economic type? |
| Valuation | Not met | Is the operating path required by today's price achievable? |
| Liquidity | Met | Can the intended position be built and exited in the right vehicle? |
| Downside | Met | Named cause: US export-control escalation extending licence requirements to KLA process-control tools for China domestic logic/mature-node and memory fabs. |
| Momentum | Met | Does price action support or complicate entry timing? |
| Catalyst | Met | Is there a dated event that resolves the disagreement? |
| Consensus | Met | Is the house-versus-Street disagreement identified and quantified? |
Quality, valuation and liquidity can prevent a position on their own. The remaining four inform timing, sizing and monitoring, and never reject an investment by themselves.
The gap between what today's price requires and what the business has demonstrated is -13.4 percentage points, and that gap — not the multiple — is the case that the security is mispriced. The most important unresolved uncertainty is the permanent-loss mechanism: named cause: US export-control escalation extending licence requirements to KLA process-control tools for China domestic logic/mature-node and memory fabs. The next evidence that should change the portfolio decision is the test dated 7 August 2026, or a daily close below $139.83, which forces an immediate review.